Compound: mizoribine
SMILES: O=C(N)c1ncn(c1O)[C@@H]2O[C@H](CO)[C@H]([C@H]2O)O
InChIKey: HZQDCMWJEBCWBR-UUOKFMHZSA-N
Synonyms: mizoribine, 50924-49-7, Mizoribina, Mizoribinum, 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide, 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide, 4JR41A10VP, DTXSID8045777, NSC-289637, DTXCID6025777, 1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-, 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide, 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide, RefChem:819016, 637-144-4, HE-69, 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide, 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide, MFCD00057221, MLS000028813, Bredinine, SMR000058473, 1H-Imidazole-4-carboxamide, 5-hydroxy-1-b-D-ribofuranosyl-, NCGC00094087-01, N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide, Mizoribine [INN:JAN], Mizoribinum [INN-Latin], Mizoribina [INN-Spanish], HE 69, Bredinin (TN), 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide, CAS-50924-49-7, SR-01000075989, BRN 4151713, UNII-4JR41A10VP, 1H-Imidazole-4-carboxamide, 5-hydroxy-1-.beta.-D-ribofuranosyl-, 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate, Mizoribine?, NSC 289637;HE 69, Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide, HS-0046, Mizoribine (Bredinin), Mizoribine (Standard), Mizoribine Hydrobromide, MIZORIBINE [MI], MIZORIBINE [INN], MIZORIBINE [JAN], Opera_ID_1558, Spectrum2_001559, Spectrum3_000739, Spectrum4_000220, Spectrum5_001671, Mizoribine (JP17/INN), M 3047, MIZORIBINE [MART.], SCHEMBL7118, MIZORIBINE [WHO-DD], Lopac0_000745, BSPBio_002298, KBioGR_000859, MLS001076272, MLS006010038, DivK1c_000948, SPBio_001438, CHEMBL245019, cid_104762, orb1309469, orb3141412, Mizoribine, >=98% (TLC), BDBM68669, CHEBI:31858, HMS502P10, KBio1_000948, KBio3_001518, HZQDCMWJEBCWBR-UUOKFMHZSA-N, NINDS_000948, GLXC-10546, HMS2230D04, HMS3262E12, 50924-49-7 (non-salt), EX-A2256, Tox21_111242, Tox21_500745, CCG-39778, FD9057, HY-17470R, s1384, AKOS015994615, Tox21_111242_1, AC-5266, CS-1823, DB12617, EBC-616626, LP00745, NM09731, NSC 289637, SDCCGSBI-0050723.P004, IDI1_000948, SMP1_000195, NCGC00094087-02, NCGC00094087-03, NCGC00094087-04, NCGC00094087-05, NCGC00261430-01, BP-58612, HY-17470, SBI-0050723.P003, EU-0100745, M2399, NS00069262, D01392, AB00053323_12, AB00053323_13, Q6884708, SR-01000075989-1, SR-01000075989-4, BRD-K88061624-001-20-6, BRD-K88061624-001-21-4, 1-(?-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide, 1-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide, 5-hydroxy-1-b-D-ribofuranosyl-1H-Imidazole-4-carboxamide, 5-HYDROXY-1-.BETA.-D-RIBOFURANOSYLIMIDAZOLE-4-CARBOXAMIDE, 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide, 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide, 1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamide
Theoretical properties:
molecular_formula: C9H13N3O6
molecular_weight: 259.22 g/mol
exact_mass: 259.08043514 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 5
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 3
heavy_atom_count: 18
topological_polar_surface_area: 151 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Mizoribine is a member of imidazoles. It has a role as an anticoronaviral agent.
chembl: MIZORIBINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Mizoribine (INN; MZB; trade name Bredinin) is an immunosuppressive drug. The compound was first observed in Tokyo, Japan, in 1971. It was first isolated from the fungus Penicillium brefeldianum.  Mizoribine is an imidazole nucleoside that has been used in renal transplantation, and in steroid-resistant nephrotic syndrome, IgA nephropathy, lupus, as well as for adults with rheumatoid arthritis, lupus nephritis and other rheumatic diseases. MZB exerts its activity through selective inhibition of inosine monophosphate dehydrogenase and guanosine monophosphate synthetase, resulting in the complete inhibition of guanine nucleotide synthesis without incorporation into nucleotides. It arrests DNA synthesis in the S phase of cellular division. Thus, MZB has less toxicity than azathioprine, another immunosuppressant used for some of the same diseases.